There are some findings demonstrating that the lack of tumor regression after eradication therapy may be related to a complex process of multiple changes in the tumor immunological environment, such as lack of macrophage activity, upregulated expression of p-SHP, p-ERK, and Bcl-XL, nuclear translocation of NFATc1, and CD56+ NK cell activity. This evidence concerns the gene BCL2L1 and neoplasm.